The U.S. market dominates the IVD industry AND remains the core geographical IVD market in the world. Yet this major multi-billion-dollar IVD market is in a state of flux, trying to manage a myriad of issues, all of which collide with a huge system that costs more than any other in the world.
COVID-19 had a profound effect on the IVD diagnostic industry – some segments exploded and others languished. At this point in time, it is hard to predict how the coronavirus will impact the forecast years to 2025, but Kalorama has attempted to provide insight into the industry by conversing with market participants and government entities. It is realistic to assume the market for COVID-19 will remain a component of the IVD market as the continued prevalence of the virus and the evolving variants are expected to remain. It should be noted that the market can be uncertain and ongoing research will help determine the long-term path of the segment in the coming months to years.
Demographic aging is also one of the primary market influencing trends for IVD in the United States. Aging is associated with rising incidences and rates of prevalence for several non-infectious diseases including diabetes and cancer. Individuals over the age of 60 are estimated to average at least four times the number of clinical tests of younger individuals.
This latest report from Kalorama Information, United States Market for In Vitro Diagnostic Tests, discusses these and other trends shaping the present and future of the IVD market in America. The report discusses the following IVD market segments in the United States:
- Clinical Chemistry
- Microbiology (Traditional) – Identification and Antibiotic Susceptibility Testing (ID/AST)
- Microbiology – Molecular- Infectious Disease
- Point-of-Care (POC) Tests – Diabetes
- Point-of-Care (POC) Tests – All Other
- Immunoassays – Infectious Disease (non-POC)
- Immunoassays – Other
- Molecular – Non-infectious Disease
- Coagulation (non-POC)
- Blood Testing and Typing
In addition, the report profiles the top players in the U.S. IVD market. The profiles cover notable corporate events and developments from 2018, 2019 and 2020. Featured companies include:
- ABBOTT DIAGNOSTICS
- BECKMAN COULTER, INC. / DANAHER
- BECTON, DICKINSON AND COMPANY (BD)
- BIO-RAD LABORATORIES, INC.
- CEPHEID / DANAHER
- DANAHER CORPORATION
- HOLOGIC, INC.
- ORTHO CLINICAL DIAGNOSTICS (ORTHO)
- QIAGEN N.V.
- ROCHE DIAGNOSTICS
- SIEMENS HEALTHINEERS (SIEMENS)
- SYSMEX CORPORATION
- THERMO FISHER SCIENTIFIC INC.